- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT00137046
Efficacy and Safety of Inhaled Insulin Compared With Subcutaneous Human Insulin Therapy in Adults With Type 1 Diabetes
Efficacy and Safety of Exubera (Inhaled Insulin) Compared With Subcutaneous Human Insulin Therapy in Adult Subjects With Type 1 Diabetes Mellitus: A Long-Term, Outpatient, Open-Label, Parallel-Group Comparative Trial
This study is being done to find out the good and bad effects of a drug that is not approved for sale and the effects if any on measures of pulmonary function in adult males and females with type 1 diabetes mellitus. The drug is called EXUBERA (inhaled insulin).
This study included a 2-year comparative treatment period followed by a 6-month follow-up period during which inhaled insulin-treated subjects were switched back to subcutaneous short-acting insulin. After this follow-up period, all eligible subjects entered a comparative extension period that was to last for 5 years. When the comparative portion of the study was terminated, all subjects were requested to return for a final extension follow-up month 3 visit.
연구 개요
상세 설명
연구 유형
등록 (실제)
단계
- 3단계
연락처 및 위치
연구 장소
-
-
Col Las Americas
-
Mexico Df, Col Las Americas, 멕시코, 01120
- Pfizer Investigational Site
-
-
DF
-
Mexico, DF, 멕시코, 14000
- Pfizer Investigational Site
-
Mexico, DF, 멕시코, 02990
- Pfizer Investigational Site
-
-
Nuevo Leon
-
Monterrey, Nuevo Leon, 멕시코, 64060
- Pfizer Investigational Site
-
-
-
-
California
-
Fullerton, California, 미국, 92835
- Pfizer Investigational Site
-
Long Beach, California, 미국, 90806
- Pfizer Investigational Site
-
Sacramento, California, 미국, 95816
- Pfizer Investigational Site
-
San Diego, California, 미국, 92103
- Pfizer Investigational Site
-
Santa Barbara, California, 미국, 93105
- Pfizer Investigational Site
-
Santa Rosa, California, 미국, 95405
- Pfizer Investigational Site
-
Tustin, California, 미국, 92780
- Pfizer Investigational Site
-
Walnut Creek, California, 미국, 94598
- Pfizer Investigational Site
-
-
Colorado
-
Denver, Colorado, 미국, 80220
- Pfizer Investigational Site
-
Longmont, Colorado, 미국, 80501
- Pfizer Investigational Site
-
-
Connecticut
-
Hamden, Connecticut, 미국, 06518
- Pfizer Investigational Site
-
Madison, Connecticut, 미국, 06443
- Pfizer Investigational Site
-
-
Delaware
-
Newark, Delaware, 미국, 19713
- Pfizer Investigational Site
-
-
Florida
-
Coral Gables, Florida, 미국, 33134
- Pfizer Investigational Site
-
Hollywood, Florida, 미국, 33021
- Pfizer Investigational Site
-
Miami, Florida, 미국, 33136
- Pfizer Investigational Site
-
Tallahassee, Florida, 미국, 32308
- Pfizer Investigational Site
-
West Palm Beach, Florida, 미국, 33401
- Pfizer Investigational Site
-
Winter Park, Florida, 미국, 32789
- Pfizer Investigational Site
-
-
Illinois
-
Chicago, Illinois, 미국, 60610
- Pfizer Investigational Site
-
Chicago, Illinois, 미국, 60602
- Pfizer Investigational Site
-
Wilmette, Illinois, 미국, 60091
- Pfizer Investigational Site
-
-
Maryland
-
Bethesda, Maryland, 미국, 20817
- Pfizer Investigational Site
-
-
Missouri
-
St. Louis, Missouri, 미국, 63141
- Pfizer Investigational Site
-
-
Montana
-
Butte, Montana, 미국, 59701
- Pfizer Investigational Site
-
-
New York
-
New Hyde Park, New York, 미국, 11042
- Pfizer Investigational Site
-
-
North Carolina
-
Durham, North Carolina, 미국, 27713
- Pfizer Investigational Site
-
-
Oregon
-
Portland, Oregon, 미국, 97210
- Pfizer Investigational Site
-
-
Pennsylvania
-
Lansdale, Pennsylvania, 미국, 19446
- Pfizer Investigational Site
-
-
Texas
-
Dallas, Texas, 미국, 75230
- Pfizer Investigational Site
-
Dallas, Texas, 미국, 75246
- Pfizer Investigational Site
-
San Antonio, Texas, 미국, 78229
- Pfizer Investigational Site
-
-
Vermont
-
Burlington, Vermont, 미국, 05401
- Pfizer Investigational Site
-
-
Virginia
-
Richmond, Virginia, 미국, 23225
- Pfizer Investigational Site
-
-
Washington
-
Renton, Washington, 미국, 98057
- Pfizer Investigational Site
-
-
Wisconsin
-
Milwaukee, Wisconsin, 미국, 53209
- Pfizer Investigational Site
-
-
-
-
MG
-
Belo Horizonte, MG, 브라질, 30150-221
- Pfizer Investigational Site
-
-
PR
-
Curitiba, PR, 브라질, 80420-011
- Pfizer Investigational Site
-
-
RS
-
Porto Alegre, RS, 브라질, 90035-170
- Pfizer Investigational Site
-
Porto Alegre, RS, 브라질, 90035-903
- Pfizer Investigational Site
-
-
SP
-
Campinas, SP, 브라질, 13083-900
- Pfizer Investigational Site
-
Sao Paulo, SP, 브라질, 01244-030
- Pfizer Investigational Site
-
Sao Paulo, SP, 브라질, 04231-030
- Pfizer Investigational Site
-
São Paulo, SP, 브라질, 04020-041
- Pfizer Investigational Site
-
-
-
-
Buenos Aires
-
Capital Federal, Buenos Aires, 아르헨티나, C1120 AAF
- Pfizer Investigational Site
-
Capital Federal, Buenos Aires, 아르헨티나, C1181 ACH
- Pfizer Investigational Site
-
Capital Federal, Buenos Aires, 아르헨티나, C1405 DCS
- Pfizer Investigational Site
-
Capital Federal, Buenos Aires, 아르헨티나, C1427 AQR
- Pfizer Investigational Site
-
-
-
-
Alberta
-
Calgary, Alberta, 캐나다, T2T 5C7
- Pfizer Investigational Site
-
Calgary, Alberta, 캐나다, T3B 0M3
- Pfizer Investigational Site
-
Edmonton, Alberta, 캐나다, T5J 3N4
- Pfizer Investigational Site
-
Edmonton, Alberta, 캐나다, T6G 2C8
- Pfizer Investigational Site
-
-
British Columbia
-
Victoria, British Columbia, 캐나다, V8R 1J8
- Pfizer Investigational Site
-
-
Manitoba
-
Winnepeg, Manitoba, 캐나다, R3A 1R9
- Pfizer Investigational Site
-
Winnipeg, Manitoba, 캐나다, R3E 3P4
- Pfizer Investigational Site
-
-
Nova Scotia
-
Halifax, Nova Scotia, 캐나다, B3H 1V7
- Pfizer Investigational Site
-
Halifax, Nova Scotia, 캐나다, B3H 2Y9
- Pfizer Investigational Site
-
-
Ontario
-
Kingston, Ontario, 캐나다, K7L 2V7
- Pfizer Investigational Site
-
London, Ontario, 캐나다, N6A 4V2
- Pfizer Investigational Site
-
Mississauga, Ontario, 캐나다, L5M 2V8
- Pfizer Investigational Site
-
Oakville, Ontario, 캐나다, L6H 3P1
- Pfizer Investigational Site
-
Ottawa, Ontario, 캐나다, K1H 1A2
- Pfizer Investigational Site
-
Thornhill, Ontario, 캐나다, L4J 8L7
- Pfizer Investigational Site
-
Toronto, Ontario, 캐나다, M4R 2G4
- Pfizer Investigational Site
-
-
Quebec
-
Laval, Quebec, 캐나다, H7T 2P5
- Pfizer Investigational Site
-
Montreal, Quebec, 캐나다, H3A 1A1
- Pfizer Investigational Site
-
Montreal, Quebec, 캐나다, H1T 2M4
- Pfizer Investigational Site
-
Sherbrooke, Quebec, 캐나다, J1H 5N4
- Pfizer Investigational Site
-
-
Saskatchewan
-
Saskatoon, Saskatchewan, 캐나다, S7N 0W8
- Pfizer Investigational Site
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Type 1 diabetes mellitus
Exclusion Criteria:
- severe asthma or COPD
- smoking
- brittle diabetes
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
활성 비교기: 피하 인슐린
|
Subcutaneous insulin with dose adjusted according to premeal blood glucose
|
|
실험적: 흡입된 인슐린
|
Inhaled insulin with dose adjusted according to premeal blood glucose
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change From Baseline in Forced Expiratory Volume in One Second (FEV1)
기간: Baseline through Extension Follow-up Month 3
|
Change from Baseline: mean of (value of observed forced expiratory volume in the first second of forced exhalation [FEV1] in liters [L] at observation minus Baseline value).
|
Baseline through Extension Follow-up Month 3
|
|
Summary of ≥ 15% Decliners in Forced Expiratory Volume in One Second (FEV1)
기간: Month 3 through Extension Follow-up 3
|
Number of subjects with a post-baseline Forced Expiratory Volume in One Second (FEV1) decrease of ≥ 15 % [(baseline observed value minus visit observed value)/(baseline observed value) * 100]; in the absence of an obvious intercurrent illness, a repeat FEV1 was performed.
|
Month 3 through Extension Follow-up 3
|
|
Change From Baseline in Carbon Monoxide Diffusion Capacity (DLco)
기간: Baseline through Extension Follow-up Month 3
|
Change from Baseline: mean of (value of Carbon Monoxide Diffusing Capacity [DLco] measured in milliters/minutes/millimeters of mercury [mL/min/mmHg] at observation minus Baseline value).
|
Baseline through Extension Follow-up Month 3
|
|
Summary of ≥ 20% Decliners in Carbon Monoxide Diffusing Capacity (DLco).
기간: Month 3 through Extension Follow-up Month 3
|
Number of subjects with a post-baseline Carbon Monoxide Diffusing Capacity (DLco) decrease of ≥ 20% [(baseline observed value minus visit observed value)/(baseline observed value) * 100]; in the absence of an obvious intercurrent illness, a repeat DLco was performed.
|
Month 3 through Extension Follow-up Month 3
|
|
Annual Rate of Change in Forced Expiratory Volume in 1 Second (FEV1)
기간: Week -2 through Extension Follow-up Month 6 or end of study
|
Annual rate of change in FEV1 calculated as slope over time [visit] for forced expiratory volume in 1 second measured as liters per year (L/yr).
|
Week -2 through Extension Follow-up Month 6 or end of study
|
|
Annual Rate of Change in Carbon Monoxide Diffusion Capacity (DLco)
기간: Week -2 through Extension Follow-up Month 6 or end of study
|
Annual rate of change in DLco calculated as slope over time (visit) measured as milliliters per minute per millimeters of hemoglobin per year (ml/min/mmHg/yr).
|
Week -2 through Extension Follow-up Month 6 or end of study
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change From Baseline in Glycosylated Hemoglobin (HbA1c)
기간: Baseline through Extension Follow-up Month 3
|
Change from Baseline: mean of (value of Glycosylated Hemoglobin [HbA1c] at observation minus Baseline value).
|
Baseline through Extension Follow-up Month 3
|
|
Hypoglycemic Event Rates
기간: Month 1 through Extension Month 39
|
A Hypoglycemic event was identified by characteristic symptoms of hypoglycemia with no blood glucose check with prompt resolution with food intake, subcutaneous glucagon, or intravenouus glucose; characteristic symptoms with blood glucose of 59 milligrams per deciliter (mg/dL) (3.2 mmol/L) or less with blood glucose check; or any glucose measurement of 49 mg/dL (2.7 mmol/L) or less, with or without symptoms.
Subject months = elapsed number of months a subject was in the study in each time interval.
Crude event rate = total events divided by subject month of treatment.
|
Month 1 through Extension Month 39
|
|
Severe Hypoglycemic Event Rates
기간: Month 1 through Extension Month 39
|
Severe hypoglycemic event = all 3 of the following criteria were met: subject unable to treat self, exhbited at least 1 neurological symptom (memory loss, confusion, uncontrollable behavior, irrational behavior, unusual difficulty in awakening, suspected seizure, loss of consciousness); and blood glucose measurement was ≤49 mg/dL, or not measured but clinical manifestations reversed by oral carbohydrates, subcutaneous glucagon, or i.v.
glucose.
Subject months = elapsed number of months subject was in study in each time interval.
Crude event rate = total events divided by subject months * 100.
|
Month 1 through Extension Month 39
|
|
Change From Baseline in Fasting Plasma Glucose
기간: Baseline through Extension Follow-up Month 3
|
Change from Baseline: mean of (value of fasting plasma glucose [milligrams per deciliter (mg/dL)] at observation minus Baseline value).
|
Baseline through Extension Follow-up Month 3
|
|
Change From Baseline Body Weight
기간: Baseline through Extension Follow-up Month 3
|
Body weight: mean Baseline and change from Baseline in kilograms (kg).
Change from baseline = mean body weight in kilograms (kg) at observation minus mean baseline body weight.
|
Baseline through Extension Follow-up Month 3
|
|
Total Daily Long-Acting Insulin Dose (Unadjusted for Body Weight)
기간: Month 3 through Extension Month 39
|
Total Daily Long-Acting Insulin Dose Unadjusted for Body Weight; long-acting insulin included NPH Insulin, Ultralente, and Insulin Glargine for both groups.
|
Month 3 through Extension Month 39
|
|
Total Daily Long-Acting Insulin Dose Adjusted for Body Weight
기간: Month 3 through Extension Month 39
|
Total daily dose of long-acting insulin adjusted for body weight (units per kilogram [kg]).
Long-acting insulin included NPH Insulin, Ultralente, and Insulin Glargine for both groups.
|
Month 3 through Extension Month 39
|
|
Total Daily Short-Acting Insulin Dose (Unadjusted for Body Weight)
기간: Month 3 through Extension Month 39
|
Total daily dose of short-acting insulin unadjusted for body weight.
Short-acting insulin (mg) for the Inhaled Insulin group was Inhaled Insulin.
Short-acting insulin (unit) for the Subcutaneous Insulin group included Insulin Lispro, Insulin Aspart, and Regular Insulin.
|
Month 3 through Extension Month 39
|
|
Total Daily Short-Acting Insulin Dose Adjusted for Body Weight
기간: Month 3 through Extension Month 39
|
Total Daily Short-Acting Insulin Dose adjusted for body weight (milligrams [mg] or units divided by kilograms [kg]).
Short-acting insulin (mg) for the Inhaled Insulin group was Inhaled Insulin.
Short-acting insulin (unit) for the Subcutaneous Insulin group included Insulin Lispro, Insulin Aspart, and Regular Insulin.
|
Month 3 through Extension Month 39
|
|
Baseline Dyspnea Index (BDI)
기간: Week - 1
|
Clinician administered instrument to measure the baseline severity of breathlessness (shortness of breath) in symptomatic patients with 3 domains: functional impairment, magnitude of task, and magnitude of effort.
BDI score range 0 (very severe impairment) to 4 (no impairment) scaled to a BDI focal score (0-12).
Lower score indicates greater impairment.
|
Week - 1
|
|
Transition Dyspnea Index (TDI)
기간: Week 4 through ,Extension Follow-up Month 6 and every 6 months thereafter or end of study
|
Clinician administered instrument to measure the baseline severity of breathlessness (shortness of breath) in symptomatic patients with 3 domains: functional impairment, magnitude of task, and magnitude of effort.
TDI score range -3 (major deterioration) to +3 (major improvement); sum of all domains yields the TDI focal score (-9 to +9); lower score indicates greater deterioration.
Compared to previous scoring to determine deterioration or improvement.
|
Week 4 through ,Extension Follow-up Month 6 and every 6 months thereafter or end of study
|
|
Lipids
기간: Week -4 through Month 24
|
Total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, and triglycerides measured as milligrams per deciliter (mg/dL).
|
Week -4 through Month 24
|
|
Cough Questionnaire
기간: Week 0 and if indicated through Extension Follow up Month 3
|
Subject completed cough questionnaire with reference to the past 4 weeks.
Six question instrument to measure cough frequency (night, day), severity, timing in relation to short-acting insulin dosing, severity related to insulin dosing (subcutaneous [SC] or inhaled), and productivity of cough; range 0 (no symptoms) to 4 (severe symptoms).
Questionnaire was administered at Week 0 and then at subsequent visits only if cough was identified as an adverse event not explained by a concomitant condition, such as an upper respiratory tract infection.
|
Week 0 and if indicated through Extension Follow up Month 3
|
|
Forced Vital Capacity (FVC)
기간: Week -3 through Extension Follow-up Month 6 or End of Study
|
Forced Vital Capacity (FVC) measured in liters (L).
|
Week -3 through Extension Follow-up Month 6 or End of Study
|
|
Total Lung Capacity (TLC)
기간: Week -3 through Extension Follow-up Month 6 or End of Study
|
Total Lung Capacity measured in liters (L).
|
Week -3 through Extension Follow-up Month 6 or End of Study
|
|
Insulin Antibodies
기간: Baseline through Extension Month 39
|
Median insulin antibodies at each visit measured in micro units per milliliter (microU/mL).
|
Baseline through Extension Month 39
|
공동 작업자 및 조사자
스폰서
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .